Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 29, 2008

Abbott Snags Global Rights to Luminex’ Respiratory Viral Panel

  • Abbott gained a global sales and distribution license to Luminex' xTAG™ RVP (respiratory viral panel). Abbott has the exclusive rights to distribute the test outside the U.S. and semiexclusive rights in the U.S.

    FDA cleared xTAG RVP in January 2008 and the technology became CE marked for sale in Europe in November 2006. In the U.S., xTAG RVP has been cleared to detect 12 viruses and viral subtypes: adenovirus, influenza A (all subtypes), influenza A H1, influenza A H3, influenza B, metapneumovirus, parainfluenza 1, 2, and 3, respiratory syncytial virus (RSV) A and B, as well as rhinovirus.

    In Europe, xTAG RVP is certified to detect and identify 20 viruses and viral subtypes. These include all the targets approved in the U.S. plus corona virus 229E, HKU1, NL63, and OC43, enterovirus, influenza A H5, parainfluenza 4, and SARS.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »